CR20160562A - Péptidos como agonistas de la oxitocina - Google Patents

Péptidos como agonistas de la oxitocina

Info

Publication number
CR20160562A
CR20160562A CR20160562A CR20160562A CR20160562A CR 20160562 A CR20160562 A CR 20160562A CR 20160562 A CR20160562 A CR 20160562A CR 20160562 A CR20160562 A CR 20160562A CR 20160562 A CR20160562 A CR 20160562A
Authority
CR
Costa Rica
Prior art keywords
oxychocine
agonists
peptides
lower alkyl
cycloalkyl
Prior art date
Application number
CR20160562A
Other languages
English (en)
Inventor
Goutam Saha
Caterina Bissantz
Christophe Grundschober
Konrad Bleicher
Kanchan Chakraborty
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20160562A publication Critical patent/CR20160562A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

La invención se refiere a compuestos de fórmula en donde R1 es hidrógeno, alquilo inferior, -CH2-cicloalquilo o cicloalquilo; R2 es hidrógeno, alquilo inferior, alquilo inferior sustituido con hidroxi, o R1 y R2 pueden formar junto con el átomo de N y C al que están unidos un anillo de pirrolidina opcionalmente sustituido con uno o dos átomos de F o con hidroxi, o puede formar una azetidina o un anillo de piperidina;
CR20160562A 2014-06-06 2014-06-06 Péptidos como agonistas de la oxitocina CR20160562A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14171440 2014-06-06
PCT/EP2015/062314 WO2015185584A1 (en) 2014-06-06 2015-06-03 Peptides as oxytocin agonists

Publications (1)

Publication Number Publication Date
CR20160562A true CR20160562A (es) 2017-01-06

Family

ID=50932985

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160562A CR20160562A (es) 2014-06-06 2014-06-06 Péptidos como agonistas de la oxitocina

Country Status (16)

Country Link
US (1) US20170081368A1 (es)
EP (1) EP3152225B1 (es)
JP (1) JP6535688B2 (es)
KR (1) KR20170004014A (es)
CN (1) CN106459156A (es)
AU (1) AU2015270564A1 (es)
CA (1) CA2950493A1 (es)
CL (1) CL2016003076A1 (es)
CR (1) CR20160562A (es)
EA (1) EA030296B1 (es)
IL (1) IL248625A0 (es)
MX (1) MX2016015877A (es)
PE (1) PE20170427A1 (es)
PH (1) PH12016502251A1 (es)
SG (1) SG11201610221WA (es)
WO (1) WO2015185584A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65144B1 (sr) 2014-09-19 2024-02-29 Ferring Bv Postupak za lečenje prader-vilijevog sindroma
US20190135859A1 (en) 2017-08-11 2019-05-09 Ferring B.V. Method of manufacturing a pharmaceutical composition
CN110997697A (zh) 2017-08-11 2020-04-10 辉凌公司 制备药物组合物的方法
AU2019345313A1 (en) 2018-09-20 2021-03-18 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
US20200093884A1 (en) 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin
CN113801200B (zh) * 2021-09-28 2023-07-25 浙江湃肽生物有限公司 一种卡贝缩宫素的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483794A (en) * 1983-05-10 1984-11-20 Ceskoslovenska Akademie Ved Analogs of neurohypophysial hormones
KR20070022753A (ko) * 2004-05-26 2007-02-27 화이자 인코포레이티드 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
FR2875499B1 (fr) * 2004-09-20 2006-10-27 Sanofi Aventis Sa Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique
CN101641013B (zh) * 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
CA2718148C (en) * 2008-03-31 2017-11-07 Ferring B.V. Oxytocin analogues
BRPI0919342A2 (pt) * 2008-09-23 2015-12-29 Hoffmann La Roche derivados do isoxazol [4,5] piridin-3-il-piperazina, seu processo de preparação, seu medicamento e seu uso
KR101701533B1 (ko) * 2009-05-05 2017-02-13 에프. 호프만-라 로슈 아게 아이속사졸-피리다진 유도체
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
ES2509270T3 (es) * 2009-10-01 2014-10-17 The University Of Sydney Terapia y prevención del alcoholismo
US9585935B2 (en) 2010-07-30 2017-03-07 The Regents Of The University Of California Intranasal oxytocin treatment to improve schizophrenia

Also Published As

Publication number Publication date
EP3152225A1 (en) 2017-04-12
JP2017518313A (ja) 2017-07-06
CA2950493A1 (en) 2015-12-10
SG11201610221WA (en) 2017-01-27
IL248625A0 (en) 2017-01-31
WO2015185584A1 (en) 2015-12-10
JP6535688B2 (ja) 2019-06-26
MX2016015877A (es) 2017-03-27
EA201692488A1 (ru) 2017-05-31
CN106459156A (zh) 2017-02-22
AU2015270564A1 (en) 2016-11-17
PH12016502251A1 (en) 2017-02-06
US20170081368A1 (en) 2017-03-23
KR20170004014A (ko) 2017-01-10
EP3152225B1 (en) 2018-11-14
CL2016003076A1 (es) 2017-08-11
EA030296B1 (ru) 2018-07-31
PE20170427A1 (es) 2017-04-26

Similar Documents

Publication Publication Date Title
CR20160562A (es) Péptidos como agonistas de la oxitocina
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
CU20160162A7 (es) Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
UY34825A (es) Síntesis de compuestos heterocíclicos
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
BR112015027432B8 (pt) 3-(4-isobutil-2-metilfenil)propanal como ingrediente de perfume
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
CU20180144A7 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CR20150271A (es) Peptidos como agonistas de oxitocina
PE20210549A1 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CR20160198A (es) Derivados de etinilo-imidazolidín-2, 4-diona como moduladore mglur4
UY35333A (es) Compuestos de azabencimidazol
UY35143A (es) Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
DOP2016000242A (es) Uso de compuestos heterocíclicos para controlar nematodos
CR20160448A (es) Nuevos derivados de piridina
BR112015022162A2 (pt) sonda fluorescente de zinco
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
ES2572052T3 (es) Amidas macrocíclicas como inhibidores de proteasas
BR112016028022A2 (pt) compostos de sulfonamida e seus usos como inibidores de stat5
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
PE20161559A1 (es) Peptidos como agonistas de la oxitocina